1. Home
  2. RCS vs FDMT Comparison

RCS vs FDMT Comparison

Compare RCS & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCS
  • FDMT
  • Stock Information
  • Founded
  • RCS 1994
  • FDMT 2013
  • Country
  • RCS United States
  • FDMT United States
  • Employees
  • RCS N/A
  • FDMT N/A
  • Industry
  • RCS Investment Managers
  • FDMT Biotechnology: Pharmaceutical Preparations
  • Sector
  • RCS Finance
  • FDMT Health Care
  • Exchange
  • RCS Nasdaq
  • FDMT Nasdaq
  • Market Cap
  • RCS 355.6M
  • FDMT 420.7M
  • IPO Year
  • RCS N/A
  • FDMT 2020
  • Fundamental
  • Price
  • RCS $7.78
  • FDMT $7.79
  • Analyst Decision
  • RCS
  • FDMT Strong Buy
  • Analyst Count
  • RCS 0
  • FDMT 9
  • Target Price
  • RCS N/A
  • FDMT $46.75
  • AVG Volume (30 Days)
  • RCS 141.1K
  • FDMT 823.3K
  • Earning Date
  • RCS 01-01-0001
  • FDMT 11-13-2024
  • Dividend Yield
  • RCS 10.12%
  • FDMT N/A
  • EPS Growth
  • RCS N/A
  • FDMT N/A
  • EPS
  • RCS N/A
  • FDMT N/A
  • Revenue
  • RCS N/A
  • FDMT $17,000.00
  • Revenue This Year
  • RCS N/A
  • FDMT N/A
  • Revenue Next Year
  • RCS N/A
  • FDMT $57.85
  • P/E Ratio
  • RCS N/A
  • FDMT N/A
  • Revenue Growth
  • RCS N/A
  • FDMT N/A
  • 52 Week Low
  • RCS $4.51
  • FDMT $7.32
  • 52 Week High
  • RCS $6.31
  • FDMT $36.25
  • Technical
  • Relative Strength Index (RSI)
  • RCS 55.52
  • FDMT 38.74
  • Support Level
  • RCS $7.65
  • FDMT $8.04
  • Resistance Level
  • RCS $7.90
  • FDMT $8.96
  • Average True Range (ATR)
  • RCS 0.14
  • FDMT 0.60
  • MACD
  • RCS 0.00
  • FDMT 0.11
  • Stochastic Oscillator
  • RCS 62.16
  • FDMT 25.27

About RCS PIMCO Strategic Income Fund Inc.

PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with this objective.

About FDMT 4D Molecular Therapeutics Inc.

4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

Share on Social Networks: